Johnson & Johnson Inc is to significantly expand its presence in drugs for autoimmune diseases with the acquisition of Momenta Pharmaceuticals Inc in an all cash transaction valued at approximately $6.5 billion. Momenta’s lead product, nipocalimab, is in Phase 3 for the treatment of a rare autoimmune disorder called warm autoimmune haemolytic anaemia.
